Cargando…
Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report
BACKGROUND: While Coronavirus disease 2019 (Covid-19) vaccines are highly effective, breakthrough infections are occurring. Booster vaccinations have recently received emergency use authorization (EUA) for certain populations but are restricted to homologous mRNA vaccines. We evaluated homologous an...
Ejemplares similares
-
Homologous and Heterologous Covid-19 Booster Vaccinations
por: Atmar, Robert L., et al.
Publicado: (2022) -
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
por: Lyke, Kirsten E., et al.
Publicado: (2022) -
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
por: Lyke, Kirsten E., et al.
Publicado: (2023) -
Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial
por: Branche, Angela R., et al.
Publicado: (2023) -
2395. An Interim Report of the Safety, Reactogenicity, and Immunogenicity of a Self-amplifying mRNA (samRNA) COVID-19 Vaccine GRT-R910 as a Booster in Healthy Adults
por: Whitaker, Jennifer, et al.
Publicado: (2023)